Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma — Masatoshi Kudo (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
Shared by
Masatoshi Kudo
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
Editorial Material
2023
en
Authors
Masatoshi Kudo
Related publications
Editorial Material
2023
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Masatoshi Kudo
Editorial Material
2021
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Article
2021
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Editorial Material
2020
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Article
2020
IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation
Stephen P. Hack
,
Jessica Spahn
,
Minshan Chen
,
Ann‐Lii Cheng
,
Ahmed O. Kaseb
,
Masatoshi Kudo
,
Han Chu Lee
,
Adam C. Yopp
,
Pierce K. H. Chow
,
Shukui Qin
Discussion(0)
No comments yet. Be the first to comment.